Dogs with metastatic (spread) cancer

 Click here to download the study flyer

Purpose and Brief Explanation of Study:

Due to metastatic disease, numerous patients are not suitable candidates for surgical resection. Sometimes, some patients are not good candidates for any invasive surgical procedures due to co-morbidities: renal disease, heart disease or advanced hepatic disease that may preclude any liver resection/nephrectomy or deep prolonged anesthesia. 

 

Microwave (MW) ablation is a modality that achieves tumor necrosis through heat, which is produced by the conduction of microwave energy, MW has emerged as a promising treatment option for numerous disease processes on the human side: direct treatment of primary hepatic, renal, pancreatic, prostatic or pulmonary tumors, and treatment of distant metastases (hepatic, pulmonary or bone metastases). MW ablation appeared to be a safe, and effective treatment of soft tissue tumors in people.

 

This technology has also been used for renal or prostatic nodules in people. Versatility of this treatment is very attractive as it can be performed via a classic open approach (laparotomy or thoracotomy) but also percutaneously with ultrasound or CT guidance, allowing treatment of cancer patients with a minimal invasive approach.

Objective of the trial:

The purposes of the study are to assess clinical efficacy, to record the associated complications (intra and post-operative complications) and the potential effects on long term survival of the microwave ablation therapy for the treatment of liver/pulmonary/renal metastatic diseases.

What qualifies my dog for enrollment in this in this trial?

Dogs diagnosed with metastatic disease in the liver, a kidney or in the lungs are eligible to enroll in this study.

What does enrolling my dog in this clinical trial involve?

Dogs enrolled in this study will receive microwave ablation therapy to treat hepatic, renal or pulmonary metastatic disease. The best surgical approach (percutaneous, via thoracoscopy or laparoscopy or via an open approach) will be determined by the clinician.

Client Contact

If you believe your pet may be eligible to enter this study, please click here to fill out a questionnaire. 

Dr. Vincent Wavreille (wavreille.2@osu.edu)